Symbols

GHRS

GH Research·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 3

Consensus Rating "Strong Buy"

Ample Liquidity

Significant Net Income Decline

Shooting Star

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About GHRS

Gh Research Plc

A clinical stage biopharmaceutical company that develops novel therpies for the management of mental diseases

Industry

Pharmaceutical

Established Date

03/29/2021

Listing Date

06/25/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.ghres.com

Security Type

Common stock

Office address

Joshua Dawson House, Dawson Street, Dublin 2, D02 RY95, Ireland

Business

Introduction

GH Research PLC was incorporated under the laws of Ireland on 29 March 2021. The company is a clinical-stage biopharmaceutical company dedicated to transforming patients' lives by developing a treatment that transforms the practice of depression. The company's initial focus is on the development of new and proprietary mebufostin therapies for the treatment of patients with treatment-resistant depression (TRD). Their product portfolio currently includes GH001, a proprietary inhalable mebufostin product candidate, and GH002, a proprietary intravenous mebufostin product candidate.

Company Financials

EPS

GHRS has released its 2025 Q4 earnings. EPS was reported at -0.23, versus the expected -0.27, beating expectations. The chart below visualizes how GHRS has performed over recent quarters, highlighting trends in earnings surprises.